HomeInsightsPE

Aurobindo Pharma Ltd PE Ratio

Aurobindo Pharma Ltd PE Ratio

stocks purchased

₹ 0.9 Cr

Volume transacted

stocks purchased

6.5 K

stocks traded

Last Updated time: 17 Oct 15:30 PM

Image

Aurobindo Pharma Ltd

NSE: AUROPHARMA

PE

24

Last updated: 17 Oct 15:30 PM

Key Highlights

  • The P/E Ratio of Aurobindo Pharma Ltd is 24 as of 17 Oct 15:30 PM.
  • The P/E Ratio of Aurobindo Pharma Ltd changed from 19.5 on March 2019 to 20.1 on March 2024 . This represents a CAGR of 0.51% over 6 years. .
  • The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1468 as of 17 Oct 15:30.
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.2. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 158.1. The PE Ratio of Textiles industry is 37.6. In 2024.

Historical P/E Ratio of Aurobindo Pharma Ltd

No data available

Company Fundamentals for Aurobindo Pharma Ltd

No data available

Image

Aurobindo Pharma Ltd

NSE: AUROPHARMA

PRICE

1468.2

-14.50 (-0.98%)

stock direction

Last updated: 17 Oct 15:30

Market price Over Time

1M

1Y

3Y

5Y

Monitoring Aurobindo Pharma Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPriceleft
17 Oct 20241468.2
16 Oct 20241482.7
15 Oct 20241479.8
14 Oct 20241489.7
11 Oct 20241495.4
10 Oct 20241465.2
09 Oct 20241511.1
08 Oct 20241490.25
07 Oct 20241466.65
04 Oct 20241466.35

SWOT Analysis Of Aurobindo Pharma Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Aurobindo Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Aurobindo Pharma Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Aurobindo Pharma Ltd2386,027
Sun Pharmaceuticals Industries Ltd434,53,486
Divis Laboratories Ltd961,61,321
Cipla Ltd281,25,847
Torrent Pharmaceuticals Ltd681,14,938
Dr Reddys Laboratories Ltd201,11,799

Key Valuation Metric of Aurobindo Pharma Ltd

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical Revenue of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical EBITDA of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical Net Profit of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical Dividend Payout of Aurobindo Pharma Ltd

No data available

* All values are in %

About Aurobindo Pharma Ltd

  • Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company.
  • Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
  • APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
  • The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
  • APL is running with 24 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

Aurobindo Pharma Ltd News Hub

News

Aurobindo Pharma tumbles after US FDA issues warning letter to Telangana unit

In May 2024, the United States Food and Drug Administration (US FDA) had conducted an insp...

Read more

2024-08-16 00:00:00

News

Eugia Pharma Specialities receives USFDA warning for Unit III

Aurobindo Pharma announced that the USFDA has issued a warning letter for Unit-III of Eugi...

Read more

2024-08-16 00:00:00

News

Aurobindo Pharma consolidated net profit rises 61.05% in the June 2024 quarter

Net profit of Aurobindo Pharma rose 61.05% to Rs 919.22 crore in the quarter ended June 20...

Read more

2024-08-12 00:00:00

News

Auro Pharma gets USFDA nod for atrophic vaginitis drug

The approved drug is bioequivalent and therapeutically equivalent to the reference listed ...

Read more

2024-08-07 00:00:00

News

Aurobindo Pharma Ltd up for fifth session

Aurobindo Pharma Ltd is up for a fifth straight session in a row. The stock is quoting at ...

Read more

2024-08-28 00:00:00

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

FAQs for PE of Aurobindo Pharma Ltd

What is the current PE Ratio of Aurobindo Pharma Ltd?

The Current PE Ratio of Aurobindo Pharma Ltd is 23.98 as on 18 Oct 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 18 Oct 2024.

What was the PE Ratio of Aurobindo Pharma Ltd last year?

The PE Ratio of Aurobindo Pharma Ltd was 15.74 last year, now the PE ratio is 23.98, showing a year-on-year growth of 52.4%.

What does the PE Ratio of Aurobindo Pharma Ltd indicate about its stock?

The PE Ratio of Aurobindo Pharma Ltd is 23.98. This ratio indicates that investors are willing to pay 23.98 times the earnings per share for each share of Aurobindo Pharma Ltd.

What is the PE Ratio Growth of Aurobindo Pharma Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Aurobindo Pharma Ltd grew by 52.4% whereas, the EPS ratio grew by 1.2.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*